medius KLINIKEN gGmbH
- Address
- Hedelfinger Strasse 166, Ruit, 73760 Ostfildern, Germany
Digestive System Diseases
At medius KLINIKEN gGmbH, researchers are advancing care for gastrointestinal malignancies by evaluating new treatment sequences and personalized approaches that aim to improve survival and preserve organ function.
- Adjuvant therapy guided by circulating tumor DNA in stage II colon cancer to enhance disease‑free survival.
- Organ‑preservation strategies for intermediate and high‑risk rectal cancer using short‑course radiotherapy and consolidation chemotherapy.
- Comparison of pre‑operative chemotherapy versus risk‑adapted adjuvant therapy in locally advanced rectal cancer.
- Evaluation of neuroprotective adjuncts to reduce chemotherapy‑induced polyneuropathy in patients receiving oncologic treatment.
These initiatives reflect the site’s commitment to integrating innovative protocols into routine practice for patients with colorectal and gastric diseases.
Neoplasms
The oncology program at medius KLINIKEN focuses on testing novel drug combinations for advanced and metastatic tumors, seeking to extend overall survival and improve response rates.
- Second‑line comparison of ramucirumab + irinotecan versus ramucirumab + paclitaxel in metastatic gastric and gastro‑esophageal adenocarcinoma.
- Combination of D,L‑methadone with mFOLFOX6 for chemorefractory colorectal cancer to assess disease‑control outcomes.
- Phase‑III evaluation of pre‑operative systemic therapy in advanced colon cancer to determine impact on surgical success and long‑term survival.
- Investigation of targeted therapies in metastatic colorectal carcinoma to identify biomarkers of response.
By conducting these studies, the center aims to bring effective, personalized cancer treatments to patients across Europe.
Nervous System Diseases
Research at the site also addresses neurotoxic side effects of cancer therapy, with trials designed to prevent and mitigate peripheral nerve damage.
- Placebo‑controlled trial of Aconite Pain Oil to lower the incidence of grade II or higher chemotherapy‑induced polyneuropathy.
- Quality‑of‑life assessment for patients receiving neuroprotective interventions during neurotoxic chemotherapy.
- Exploration of integrative strategies to preserve nerve function while maintaining oncologic efficacy.
These efforts underscore the institution’s dedication to safeguarding neurological health alongside cancer treatment.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 therapeutic areas and 15 of 29 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 6 by active trials.
lock +5 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in medius KLINIKEN gGmbH
lock Showing 1 of 15 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A randomized, double-blind, placebo controlled, dose finding study to assess the efficacy and safety of SAR443122 in adult patients with moderate to severe ulcerative colitis | Sanofi-Aventis Recherche & Developpement | Phase II | Not Recruiting | May 2023 | — |
IMP list
lock Showing 1 of 29 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Fluorouracil | 6 | Unknown | 2016-11-07 | 2025-04-01 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.